In this study, we hypothesized that the RXR agonists could enhance the sensitivity of myeloma cells to lenalidomide through their heterodimer formalization with PPAR, while maintaining the regulation of blood glucose and lipid levels. The gene discussed is PPARA; the disease is plasma cell myeloma.